Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14528083 | 0.90 | HRH2 (0.66) | HRH2MAPTSIGMAR1ACHEMC4R | |
| SCHEMBL5692251 | 0.90 | HRH2 (0.66) | HRH2MAPTSIGMAR1ACHEMC4R | |
| SCHEMBL20284487 | 0.90 | HRH2 (0.66) | HRH2MAPTSIGMAR1ACHEMC4R | |
| SCHEMBL26464091 | 0.85 | NPC1 (0.62) | HRH2KDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL28161146 | 0.83 | HRH2 (0.52) | HRH2MAPTSIGMAR1ACHE | |
| SCHEMBL27979641 | 0.80 | MAPT (0.68) | HRH2MAPTSIGMAR1ACHE | |
| SCHEMBL6741206 | 0.80 | MAPT (0.68) | HRH2MAPTSIGMAR1ACHE | |
| SCHEMBL4048121 | 0.80 | MAPT (0.68) | HRH2MAPTSIGMAR1ACHE | |
| SCHEMBL14930169 | 0.80 | MC4R (0.53) | HRH2MAPTSIGMAR1ACHEMC4R | |
| SCHEMBL16882675 | 0.80 | HRH2 (0.49) | HRH2MAPTSIGMAR1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270877-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270877-A1 | IRE-1alpha INHIBITORS | XBP1, ERN1, ATF4 | HRH2 3571/4885MAPT 3426/4885SIGMAR1 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.